



ASX Announcement

Update on OKS Settlement

Melbourne, Australia, 27 July 2015

Agenix Limited (ASX: AGX) advises that it has received formal notification from OKS AGX Inc (OKS), that it has exercised its discretion under the Settlement Deed not to proceed with the assignment of Thromboview®.

As a result the intellectual property in relation to Thromboview® remains the property of the Group.

The Board will now reassess the future commercialisation prospects of the technology in light of the OKS decision and previous extensive efforts to partner this project.

The Settlement Deed terms and conditions remain in force which removed a significant legacy barrier to allowing the company to move to pursue strategic alternatives with a view to achieving an increase in shareholder value and near term revenues.

For more information please contact:

Gary Taylor
Tel: +61 (0) 430 432 745